Pipeline ++ Our Pipeline

We are advancing a pipeline of protein degraders, all discovered through our PRODEGY platform and with first-in-class potential.

Modalities
Programs (Targets)
Discovery
Lead Optimization
IND Enabling
Phase 1
Ownership
Bifunctional Degraders
BTX-9341 (CDK4/6)
HR+/HER2- Breast Cancer Resistant to CDK4/6i

BTX-9341 is a first-in-class, oral degrader of CDK4/6, important targets for a range of cancers and clinically validated in HR+/HER2- breast cancer. In preclinical breast cancer models, BTX-9341 demonstrated superiority to CDK4/6 inhibitors through potent and highly selective catalytic degradation of CDK4 and CDK6, robust inhibition of Cyclin E and CDK2 transcription, cell cycle arrest and ultimately superior in vivo efficacy in breast cancer xenografts. Beyond this increased efficacy potential, BTX-9341 is differentiated from CDK4/6 inhibitor approaches through the ability to overcome key resistance mechanisms that limit the impact of inhibitors in second line HR+/HER2- breast cancer (~70% have acquired resistance to CDK4/6 inhibitors). This exciting, new breast cancer therapy began a Phase 1 clinical trial in the third quarter of 2024.

Ownership Logo - 1742
PDE4
Inflammatory Diseases

We are exploring collaboration opportunities for our first-in-class degraders of Phosphodiesterase 4 (PDE4), a highly validated target for auto-immune and inflammatory diseases. Our PDE4 degraders are highly selective picomolar degraders of the PDE4D isoform that have shown up to 4,000-fold superior potency compared to PDE4 and JAK1/JAK2 inhibitors in inhibition of key inflammatory cytokines such as TNF-α, IFN-γ and IL-1β in preclinical models. We also believe the design of our PDE4 degraders has the potential to avoid key tolerability issues experienced by patients taking PDE4 inhibitors, enabling an overall favorable profile relative to other oral agents used for inflammatory diseases.

Ownership Logo - 1535
Molecular Glues
Undisclosed
Oncology

Biotheryx has an ongoing research collaboration and license agreement with our pharmaceutical partner, Incyte, to discover and develop molecular glue degraders for historically undruggable novel targets.

Ownership Logo - 1531
Undisclosed
Oncology

Biotheryx has an ongoing research collaboration and license agreement with our pharmaceutical partner, Incyte, to discover and develop molecular glue degraders for historically undruggable novel targets.

Ownership Logo - 1934
Bifunctionals, Glues & DACs
Undisclosed
Various

We are leveraging our PRODEGY platform to develop bifunctional degraders, molecular glues, and degrader-antibody conjugates to pursue challenging targets that may benefit from degradation.

Ownership Logo - 1845
Programs (Targets): BTX-9341 (CDK4/6)
Modalities: Bifunctional Degraders
HR+/HER2- Breast Cancer Resistant to CDK4/6i
Phase 1

BTX-9341 is a first-in-class, oral degrader of CDK4/6, important targets for a range of cancers and clinically validated in HR+/HER2- breast cancer. In preclinical breast cancer models, BTX-9341 demonstrated superiority to CDK4/6 inhibitors through potent and highly selective catalytic degradation of CDK4 and CDK6, robust inhibition of Cyclin E and CDK2 transcription, cell cycle arrest and ultimately superior in vivo efficacy in breast cancer xenografts. Beyond this increased efficacy potential, BTX-9341 is differentiated from CDK4/6 inhibitor approaches through the ability to overcome key resistance mechanisms that limit the impact of inhibitors in second line HR+/HER2- breast cancer (~70% have acquired resistance to CDK4/6 inhibitors). This exciting, new breast cancer therapy began a Phase 1 clinical trial in the third quarter of 2024.

Commercial Rights:
Commercial Rights - 1742
Programs (Targets): PDE4
Modalities: Bifunctional Degraders
Inflammatory Diseases
Lead Optimization

We are exploring collaboration opportunities for our first-in-class degraders of Phosphodiesterase 4 (PDE4), a highly validated target for auto-immune and inflammatory diseases. Our PDE4 degraders are highly selective picomolar degraders of the PDE4D isoform that have shown up to 4,000-fold superior potency compared to PDE4 and JAK1/JAK2 inhibitors in inhibition of key inflammatory cytokines such as TNF-α, IFN-γ and IL-1β in preclinical models. We also believe the design of our PDE4 degraders has the potential to avoid key tolerability issues experienced by patients taking PDE4 inhibitors, enabling an overall favorable profile relative to other oral agents used for inflammatory diseases.

Commercial Rights:
Commercial Rights - 1535
Programs (Targets): Undisclosed
Modalities: Molecular Glues
Oncology
Lead Optimization

Biotheryx has an ongoing research collaboration and license agreement with our pharmaceutical partner, Incyte, to discover and develop molecular glue degraders for historically undruggable novel targets.

Commercial Rights:
Commercial Rights - 1531
Programs (Targets): Undisclosed
Modalities: Molecular Glues
Oncology
Discovery

Biotheryx has an ongoing research collaboration and license agreement with our pharmaceutical partner, Incyte, to discover and develop molecular glue degraders for historically undruggable novel targets.

Commercial Rights:
Commercial Rights - 1934
Programs (Targets): Undisclosed
Modalities: Bifunctionals, Glues & DACs
Various
Discovery

We are leveraging our PRODEGY platform to develop bifunctional degraders, molecular glues, and degrader-antibody conjugates to pursue challenging targets that may benefit from degradation.

Commercial Rights:
Commercial Rights - 1845
background image

Pipeline ++ Partner With Us

Our Business Development team works hand in hand with our Research and Development team to thoughtfully identify prospective external opportunities that are aligned with Biotheryx’s mission and pipeline. We also actively seek discovery, development and commercialization partners, with the goal of accelerating the advancement of our novel targeted protein degraders.

Biotheryx collaborates with leading academic institutions and biopharmaceutical companies to enhance our discovery and development efforts. If you have a proposal or interest in a partnership, please contact us at [email protected].

Incyte Collaboration

In April 2023, Biotheryx entered into a research collaboration and license agreement with Incyte to discover and develop targeted protein degraders for multiple historically undruggable novel oncology targets.

Biotheryx will leverage its distinctive Cereblon-based PRODEGY platform to discover and design degraders with an initial focus on molecular glue degraders. Read the announcement press release to learn more.